Last reviewed · How we verify
Hangzhou YuYuan Bioscience Technology Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Follitrope PFS | Follitrope PFS | phase 3 | Gonadotropin (recombinant FSH) | FSH receptor (FSHR) | Reproductive Medicine / Fertility | |
| Gonal-f pen | Gonal-f pen | phase 3 | Recombinant gonadotropin (FSH) | FSH receptor (FSHR) | Reproductive/Fertility |
Therapeutic area mix
- Reproductive Medicine / Fertility · 1
- Reproductive/Fertility · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- LG Life Sciences · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Hangzhou YuYuan Bioscience Technology Co., Ltd.:
- Hangzhou YuYuan Bioscience Technology Co., Ltd. pipeline updates — RSS
- Hangzhou YuYuan Bioscience Technology Co., Ltd. pipeline updates — Atom
- Hangzhou YuYuan Bioscience Technology Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Hangzhou YuYuan Bioscience Technology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hangzhou-yuyuan-bioscience-technology-co-ltd. Accessed 2026-05-16.